This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Integra LifeSciences Reports Fourth Quarter 2012 Financial Results

The International segment revenues reflect sales that are actively managed by our International division. This does not constitute all recorded sales outside the U.S., as some Instrument and Private Label product sales in those regions are managed by their respective U.S. divisions. Therefore, from a geographic perspective, Non-U.S. revenue (see below) exceeds that of our International segment.

Worldwide product category revenues are as follows:

(In thousands) 

  Three Months Ended December 31, Twelve Months Ended December 31,
  2012 2011 Change 2012 2011 Change
WW Orthopedics* $93,279 $89,504 4.2% $369,312 $328,933 12.3%
U.S. 78,902 74,164 6.4% 312,868 271,837 15.1%
Non-U.S. 14,377 15,340 (6.3)% 56,444 57,096 (1.1)%
             
WW Neurosurgery 74,028 69,409 6.7% 277,527 272,538 1.8%
U.S. 45,268 43,217 4.7% 170,735 165,283 3.3%
Non-U.S. 28,760 26,192 9.8% 106,792 107,255 (0.4)%
             
WW Instruments 47,125 44,610 5.6% 184,032 178,607 3.0%
U.S. 40,573 38,241 6.1% 159,227 152,826 4.2%
Non-U.S. 6,552 6,369 2.9% 24,805 25,781 (3.8)%
             
Total Revenue $214,432 $203,523 5.4% $830,871 $780,078 6.5%

* The WW Orthopedics revenue category includes segment revenue from U.S. Extremities, U.S. Spine & Other, and International segment revenue related to those product areas.

6 of 9

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,024.06 +183.54 1.03%
S&P 500 2,108.29 +22.78 1.09%
NASDAQ 5,005.3910 +63.9670 1.29%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs